PMI

#4745
Picard Medical, Inc. Common Stock
4.6 0 USD
+0.03%
Market Price
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
4.56
4.70
Range Annuel
0.09
13.68
Changement quotidien
+3.14%
Changement Mensuel
+26.72%
Evolution sur 6 mois
+333.96%
Changement Annuel
-23.97%
Clôture Précédente
4.4 6
Open
4.7 0
Low
4.5 6
High
4.7 0
Volume
72
Afficher le graphique complet

Financials

Aperçu Relevé Statistiques Dividendes Documents

2026

Current report, 19 Aug 2026
Picard Medical, Inc. current report, 19 August 2026
8-K
Current report, Q3 FY2026
Picard Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Picard Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Picard Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Picard Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Picard Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Picard Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Picard Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Picard Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Picard Medical, Inc. current report, Q2 FY2026
8-K

Picard Medical, Inc. current report, Q1 FY2026

Full document

Picard Medical, Inc. (PMI) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K covers events occurring on March 10, 2026, regarding a special meeting of stockholders held virtually by Picard Medical, Inc. The company is incorporated in Delaware and trades on the NYSE American under the symbol "PMI". As of the record date (February 6, 2026), there were 73,701,176 shares of common stock outstanding.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Voting Results

Approximately 57.16% of outstanding shares were represented at the Special Meeting. Stockholders voted on two primary proposals:

  1. Amendment to Certificate of Incorporation: To increase authorized capital stock from 180,000,000 to 330,000,000 shares (including an increase in authorized common stock from 150,000,000 to 300,000,000).
    • Result: Approved (41,731,889 For; 395,329 Against; 1,851 Abstentions).
  2. Approval of Share Issuance: To approve the issuance of additional common stock exceeding 20% of outstanding shares pursuant to a securities purchase agreement with HT Investments MA LLC and High Trail Special Situations LLC, to comply with NYSE American Rule 713.
    • Result: Approved (41,715,455 For; 319,789 Against; 1,509 Abstentions).

Guidance, Outlook, and Risks

The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the context of complying with NYSE American listing rules. The issuance of shares exceeding 20% of outstanding stock was a necessary step to satisfy exchange requirements related to the securities purchase agreement.

Investor Verification Checklist

  • Verify the terms of the securities purchase agreement with HT Investments MA LLC and High Trail Special Situations LLC referenced in Proposal 2.
  • Confirm the impact of the increased authorized share count (330,000,000 total) on potential future dilution.
  • Review the February 19, 2026 Proxy Statement for detailed rationale behind the capital structure changes.
  • Check subsequent filings for the actual execution and pricing of the share issuance approved in Proposal 2.